|
1
|
Kudo M, Kitano M, Sakurai T and Nishida N:
General rules for the clinical and pathological study of primary
liver cancer, nationwide follow-up survey and clinical practice
guidelines: The outstanding achievements of the liver cancer study
group of Japan. Dig Dis. 33:765–770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lafaro KJ, Demirjian AN and Pawlik TM:
Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am.
24:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moradpour D and Blum HE: Pathogenesis of
hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 17:477–483.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chonprasertsuk S and Vilaichone RK:
Epidemiology and treatment of hepatocellular carcinoma in Thailand.
Jpn J Clin Oncol. 47:294–297. 2017.PubMed/NCBI
|
|
7
|
Levrero M: Viral hepatitis and liver
cancer: The case of hepatitis C. Oncogene. 25:3834–3847. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mazzoccoli G, Miele L, Oben J, Grieco A
and Vinciguerra M: Biology, epidemiology, clinical aspects of
hepatocellular carcinoma and the role of sorafenib. Curr Drug
Targets. 17:783–799. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Worns MA and Galle PR: Hepatocellular
carcinoma in 2017: Two large steps forward, one small step back.
Nat Rev Gastroenterol Hepatol. 15:74–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Patop IL and Kadener S: circRNAs in
cancer. Curr Opin Genet Dev. 48:121–127. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu T, Wang Y, Fan Y, Fang N, Wang T, Xu T
and Shu Y: CircRNAs in cancer metabolism: A review. J Hematol
Oncol. 12:902019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Szabo L and Salzman J: Detecting circular
RNAs: Bioinformatic and experimental challenges. Nat Rev Genet.
17:679–692. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haque S and Harries LW: Circular RNAs
(circRNAs) in health and disease. Genes (Basel). 8:3532017.
View Article : Google Scholar
|
|
14
|
Han B, Chao J and Yao H: Circular RNA and
its mechanisms in disease: From the bench to the clinic. Pharmacol
Ther. 187:31–44. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Akhter R: Circular RNA and Alzheimer's
disease. Adv Exp Med Biol. 1087:239–243. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu L, Jiang Z, Li T, Hu Y and Guo J:
Circular RNAs in hepatocellular carcinoma: Functions and
implications. Cancer Med. 7:3101–3109. 2018. View Article : Google Scholar
|
|
17
|
Hu J, Li P, Song Y, Ge YX, Meng XM, Huang
C, Li J and Xu T: Progress and prospects of circular RNAs in
hepatocellular carcinoma: Novel insights into their function. J
Cell Physiol. 233:4408–4422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng J, Zhang H, Banerjee S, Li Y, Zhou
J, Yang Q, Tan X, Han P, Fu Q, Cui X, et al: A comprehensive
assessment of next-generation sequencing variants validation using
a secondary technology. Mol Genet Genomic Med. 7:e007482019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Shang P, Li Q, Wang L, Chamba Y,
Zhang B, Zhang H and Wu C: iTRAQ-based proteomic analysis reveals
key proteins affecting muscle growth and lipid deposition in pigs.
Sci Rep. 7:467172017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cui S, Qian Z, Chen Y, Li L, Li P and Ding
H: Screening of up- and downregulation of circRNAs in HBV-related
hepatocellular carcinoma by microarray. Oncol Lett. 15:423–432.
2018.PubMed/NCBI
|
|
22
|
Chen Y, Yang F, Fang E, Xiao W, Mei H, Li
H, Li D, Song H, Wang J, Hong M, et al: Circular RNA circAGO2
drives cancer progression through facilitating HuR-repressed
functions of AGO2-miRNA complexes. Cell Death Differ. 26:1346–1364.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blum HE: Molecular therapy and prevention
of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int.
2:11–22. 2003.PubMed/NCBI
|
|
24
|
Grandhi MS, Kim AK, Ronnekleiv-Kelly SM,
Kamel IR, Ghasebeh MA and Pawlik TM: Hepatocellular carcinoma: From
diagnosis to treatment. Surg Oncol. 25:74–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Skoda AM, Simovic D, Karin V, Kardum V,
Vranic S and Serman L: The role of the Hedgehog signaling pathway
in cancer: A comprehensive review. Bosn J Basic Med Sci. 18:8–20.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhuang H, Cao G, Kou C and Liu T:
CCL2/CCR2 axis induces hepatocellular carcinoma invasion and
epithelial-mesenchymal transition in vitro through
activation of the Hedgehog pathway. Oncol Rep. 39:21–30.
2018.PubMed/NCBI
|
|
27
|
Liu Y, Huber RM, Kiefl R, Tufman A and
Kauffmann-Guerrero D: Hedgehog pathway activation might mediate
pemetrexed resistance in NSCLC cells. Anticancer Res. 40:1451–1458.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang C, Zheng X, Ye K, Sun Y, Lu Y, Fan Q
and Ge H: miR-135a inhibits the invasion and migration of
esophageal cancer stem cells through the Hedgehog signaling pathway
by targeting Smo. Mol Ther Nucleic Acids. 19:841–852. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma Y, Li G, Hu J, Liu X and Shi B:
MicroRNA-494 regulates Gli3 expression and inhibits pancreatic
cancer cells growth and migration. J Cell Biochem. 119:5324–5331.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hyun J, Wang S, Kim J, Rao KM, Park SY,
Chung I, Ha CS, Kim SW, Yun YH and Jung Y: MicroRNA-378 limits
activation of hepatic stellate cells and liver fibrosis by
suppressing Gli3 expression. Nat Commun. 7:109932016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liang Z, Liu Z, Cheng C, Wang H, Deng X,
Liu J, Liu C, Li Y and Fang W: VPS33B interacts with NESG1 to
modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce
5-fluorouracil sensitivity in nasopharyngeal carcinoma. Cell Death
Dis. 10:3052019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang W, Ju HY and Tian XF: Circular
RNA-ABCB10 suppresses hepatocellular carcinoma progression through
upregulating NRP1/ABL2 via sponging miR-340-5p/miR-452-5p. Eur Rev
Med Pharmacol Sci. 24:2347–2357. 2020.PubMed/NCBI
|
|
33
|
Shang H, Sun L, Braun T, Si Q and Tong J:
Association between miR-124 rs531564 and miR-100 rs1834306
polymorphisms and cervical cancer: A meta-analysis. Eur J Gynaecol
Oncol. 40:925–931. 2019.
|
|
34
|
Liu B, Shyr Y, Cai J and Liu Q: Interplay
between miRNAs and host genes and their role in cancer. Brief Funct
Genomics. 18:255–266. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Y, Li C, Tan C and Liu X: Circular
RNAs: A new frontier in the study of human diseases. J Med Genet.
53:359–365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhi XH, Jiang K, Ma YY and Zhou LQ:
OIP5-AS1 promotes the progression of gastric cancer cells via the
miR-153-3p/ZBTB2 axis. Eur Rev Med Pharmacol Sci. 24:2428–2441.
2020.PubMed/NCBI
|
|
37
|
Zuo J, Zhao M, Fan Z, Liu B, Wang Y, Li Y,
Lv P, Xing L, Zhang X and Shen H: MicroRNA-153-3p regulates cell
proliferation and cisplatin resistance via Nrf-2 in esophageal
squamous cell carcinoma. Thorac Cancer. 11:738–747. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chang AC, Lien MY, Tsai MH, Hua CH and
Tang CH: WISP-1 promotes epithelial-mesenchymal transition in oral
squamous cell carcinoma cells via the miR-153-3p/Snail axis.
Cancers (Basel). 11:19032019. View Article : Google Scholar
|
